ImageneBio, Inc. Lease, Cost
ImageneBio, Inc. (IMA) reported Lease, Cost of $4.30 million for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-06.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:LeaseCost · last filed 2025-03-06
- ImageneBio, Inc. lease, cost for fiscal 2024 was $4.30M, a 34.10% increase from fiscal 2023.
- ImageneBio, Inc. lease, cost for fiscal 2023 was $3.21M, a 43.72% increase from fiscal 2022.
- ImageneBio, Inc. lease, cost for fiscal 2022 was $2.23M, a 2.67% increase from fiscal 2021.
- ImageneBio, Inc. lease, cost for fiscal 2021 was $2.17M, a 26.50% increase from fiscal 2020.
| Period end | Lease, Cost 12 month |
|---|---|
| 2024-12-31 | $4.30M 10-K · filed 2025-03-06 |
| 2023-12-31 | $3.21M 10-K · filed 2025-03-06 |
| 2022-12-31 | $2.23M 10-K · filed 2024-03-12 |
| 2021-12-31 | $2.17M 10-K · filed 2023-03-14 |
| 2020-12-31 | $1.72M 10-K · filed 2022-03-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |
| EXOZYMES INC. (EXOZ) | United States | $0.058B | |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| Instil Bio, Inc. (TIL) | United States | $0.048B | -1.73 |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |
| Metagenomi Therapeutics, Inc. (MGX) | United States | $0.044B | -0.48 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B |